Mr. Rene Goehrum reports

BIOSYENT ANNOUNCES CLOSING OF THE ACQUISITION OF ORAL SCIENCE INC.

BioSyent Inc. has successfully closed the previously announced acquisition of Oral Science Inc., a privately owned Canadian distributor of specialized health care products for dental hygiene and oral health based in Brossard, Que.

Pursuant to the terms of a share purchase agreement (SPA) dated Feb. 8, 2026, BioSyent, through its wholly owned subsidiary, completed the acquisition of Oral Science from the shareholders of Oral Science in an arm's-length transaction. The aggregate purchase price was $25.5-million, satisfied by: (i) a cash payment of $22.5-million to the sellers, of which $200,000 will be satisfied with the grant of 12,666 restricted share units (RSUs) to certain Oral Science employees pursuant to BioSyent's RSU plan, which will fully vest on the second anniversary of the grant date; and (ii) the issue of 234,192 BioSyent common shares to the sellers at a deemed issue price of $12.81 per share ($3.0-million in aggregate). One hundred sixty-seven thousand six hundred thirty-five of the consideration shares are subject to a two-year escrow and 66,557 are subject to a two-year lock-up, with 25 per cent of the locked up shares to be released every six months. BioSyent paid to the sellers additional cash consideration of $2.0-million on closing, representing the excess working capital of Oral Science above the $6.3-million working capital requirement pursuant to the SPA. The sellers are also entitled to a contingent cash earnout payment in 2027 based on the performance of the Oral Science business in 2025 and 2026, as well as contingent royalty payments until 2033 based on the future sales of one product up to a maximum value of $6.0-million. No finders' fees were applicable in respect of this transaction. The cash component of the purchase consideration was financed with $16.3-million of BioSyent's liquid cash on hand along with a $6.0-million one-year senior secured demand term loan from Royal Bank of Canada and a $2.0-million draw on an RBC senior secured demand revolving credit line facility.

This transaction qualifies as an expedited acquisition under TSX Venture Exchange Policy 5.3, Acquisitions and Dispositions of Non-Cash Assets, and remains subject to final approval by the TSX-V. For more information on this transaction, please refer to BioSyent's news release dated Feb. 9, 2026.

BioSyent further announces that its board of directors has approved a grant of 8,682 RSUs to certain employees pursuant to BioSyent's restricted share unit plan. These RSUs will fully vest on the third anniversary of the grant date.

About Oral Science Inc.

Founded in Canada in 2003, Oral Science is a leading and innovative Canadian dental company that partners with progressive dental practices to improve clinical outcomes in periodontal disease, high-risk caries, dry mouth and oral lesions. Supported by advanced health care technologies, Oral Science's integrated approach is built on four key pillars: diagnosis and monitoring, in-office treatments, home-care solutions, and clinical team and patient education.

About BioSyent Inc.

Listed on the TSX Venture Exchange under the trading symbol RX, BioSyent is a profitable growth-oriented specialty health care company focused on acquiring or in-licensing, marketing and distributing innovative pharmaceutical and oral health products that have been successfully developed, are safe and effective, and have a proven record of improving the lives of patients. BioSyent supports the healthcare professionals that treat these patients by marketing its products through its Canadian pharma, international pharma and oral health business units. As of the date of this news release, the company has 11,497,447 common shares outstanding.

We seek Safe Harbor.